GSK ar­gues against tak­ing Te­va 'skin­ny' la­bel suit to SCO­TUS

GSK has once again asked the Supreme Court not to hear its case with Te­va over so-called “skin­ny” la­bels, mean­ing a gener­ic is on­ly ap­proved for some of the ref­er­ence prod­uct’s in­di­ca­tions.

The case traces back to GSK’s win against Te­va in 2017 in a court bat­tle over Te­va’s skin­ny’s la­bel for its gener­ic ver­sion of GSK’s be­ta-block­er Coreg (carvedilol). Te­va’s la­bel ini­tial­ly in­clud­ed two of the three Coreg in­dic­tions, but didn’t in­clude a third in­di­ca­tion for con­ges­tive heart fail­ure. GSK sued Te­va in 2014, sev­en years af­ter the gener­ic launched — ac­cus­ing the gener­ics gi­ant of in­fringe­ment by en­cour­ag­ing doc­tors to use the gener­ic in a not-ap­proved in­di­ca­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER